Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug 25;15(8):e44127.
doi: 10.7759/cureus.44127. eCollection 2023 Aug.

Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male

Affiliations
Case Reports

Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male

Shahman Shahab et al. Cureus. .

Abstract

Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disease that can have an ambiguous clinical presentation. A key component of the pathophysiology of WM is bone marrow infiltration, which most commonly presents as anemia. Other symptoms of WM tend to be generalized and non-specific, which presents a diagnostic challenge. This was the case with our patient as well, when he presented to our outpatient clinic with non-specific symptoms. We present a 79-year-old male with longstanding pancytopenia, polyarthralgia, bilateral pedal edema, decreased appetite, and increased bleeding from wounds. The patient had a complete blood count (CBC) and complete metabolic panel (CMP) done, confirming present anemia, which prompted inpatient treatment and an oncology workup, confirming WM. The patient began a zanubrutinib monotherapy regimen, showing improvement in his pancytopenia, polyarthralgia, and overall symptoms.

Keywords: bone marrow aspirate; bruton tyrosine kinase inhibitor; cxcr4; hyperviscosity syndrome; kappa-lambda ratio; large b-cell lymphoma; monoclonal igm gammopathy; pancytopenia; waldenstrom; waldenstroms macroglobulinemia.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. RDW values from distinct hospital visits
Grey bar represents RDW normal range of 11.5% to 14.5% † First time patient presented to the clinic. †† Patient started on Zanubrutinib *Pre-transfusion hospitalization **Visits during which the patient received a blood transfusion RDW: Red cell distribution width

Similar articles

References

    1. Waldenstrom's macroglobulinemia: an update. Mazzucchelli M, Frustaci AM, Deodato M, Cairoli R, Tedeschi A. Mediterr J Hematol Infect Dis. 2018;10:0. - PMC - PubMed
    1. Waldenström macroglobulinemia: review of pathogenesis and management. Yun S, Johnson AC, Okolo ON, et al. Clin Lymphoma Myeloma Leuk. 2017;17:252–262. - PMC - PubMed
    1. Waldenström macroglobulinemia: clinical presentation, diagnosis, and management. Hobbs M, Fonder A, Hwa YL. J Adv Pract Oncol. 2020;11:381–389. - PMC - PubMed
    1. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Br J Haematol. 2015;169:81–89. - PubMed
    1. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Kastritis E, Kyrtsonis MC, Morel P, et al. Haematologica. 2015;100:0. - PMC - PubMed

Publication types

LinkOut - more resources